Posted by Michael Wonder on 09 Jan 2017
BioCryst receives Health Canada approval for Rapivab for the treatment of influenza
8 January 2017 - BioCryst Pharmaceuticals today announced that Health Canada has approved Rapivab (peramivir injection), an intravenous treatment for acute, uncomplicated influenza.
Rapivab is approved by the U.S. FDA and is also licensed for use in Japan and Taiwan as Rapiacta and in Korea as PeramiFlu.
“This Rapivab approval represents an important milestone for BioCryst and for our partner, Seqirus,” said Jon P. Stonehouse, President & Chief Executive Officer. “We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.”
Rapivab is being commercialized by Seqirus globally, excluding Japan, Taiwan, Korea and Israel. Seqirus is a leader in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets.
